Peloton Therapeutics is a clinical-stage biotechnology company that discovers and develops first-in-class, small molecule cancer therapies targeting unexploited molecular vulnerabilities. Peloton Therapeutics' lead program, PT2385, is a first-in-class small molecule targeting hypoxia-inducible factor-2α (HIF-2α), a transcription factor implicated in the development and progression of kidney and other cancers.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/15/16 | $52,400,000 | Series D |
Foresite Capital Nextech Invest Remeditex Ventures The Column Group Tichenor Ventures Topspin Fund | undisclosed |
| 03/21/17 | $22,200,000 | Series D |
